One of the most significant advances in brain tumour research is the use oftargeted therapy. This type of treatment focuses on specific genetic mutations in the tumour cells, allowing for a more precise and effective way of attacking the cancer. For example, the drug temozolomide is a chemotherapy drug that is specifically targeted to brain tumours with a specific genetic mutation, the MGMT promoter methylation status. This type of targeted therapy has been shown to have a positive impact on patient outcomes, extending survival and improving quality of
life for those living with brain tumours.